Cooley advised ACELYRIN, and Davis Polk advised the joint book-running managers. ACELYRIN, INC. announced its upsized initial public offering of 34,500,000 shares of common stock at...
ACELYRIN’s $621 Million Initial Public Offering
ACELYRIN’s $300 Million Series C Financing Round
Goodwin Procter advised ACELYRIN on the deal. ACELYRIN announced the completion of its $300 million Series C financing round which was led by Access Biotechnology with participation...